Biogen Idec Licenses Neurimmune Nerve-Disorder-Drugs

Biogen Idec acquires additional therapeutics from the Swiss drug company, Neurimmune, as it further invests in developing drugs for ALS and other neurodegenerative diseases with unmet medical need.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail